...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Pulmonary Oligometastases Treated by Stereotactic Body Radiation Therapy: A Nationwide Survey of 1,378 Patients
【24h】

Pulmonary Oligometastases Treated by Stereotactic Body Radiation Therapy: A Nationwide Survey of 1,378 Patients

机译：立体定向体放射治疗治疗的肺部寡粒子：1,378例患者的全国范围

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: This study was performed to confirm the superior overall survival (OS) after pulmonary oligo-recurrence compared to pulmonary sync-oligometastases in a large nationwide study. Patients and Methods: Patients that met the following criteria were included: 1 to 5 lung-only metastases at the beginning of stereotactic body radiation therapy (SBRT) was performed between January 2004 and June 2015, and the biological effective dose (BED) of SBRT was 75 Gy or more. The parameters included in the analyses were age, gender, ECOG PS, primary lesion, pathology, oligoetastatic state, SBRT date, chemotherapy before SBRT, chemotherapy concurrent SBRT, chemotherapy after SBRT, maximum tumor diameter, number of metastases, field coplanarity, dose prescription, BED10, OTT of SBRT. Results: In total, 1,378 patients with 1,547 tumors were enrolled. Oligo-recurrence occurred in 1,016 patients, sync-oligometastases in 118, and unclassified oligometastases in 121. The three-year OS was 64.0% for oligorecurrence and 47.5% for sync-oligometastasis (p<0.001). In the multivariate analysis, the hazard ratio (HR) for sync-oligometastases versus oligo-recurrence was 1.601 (p=0.014). Adverse events of Grade 5 were occurred in 3 patients. Conclusion: This is the first nationwide to indicate that the OS of patients with pulmonary oligo-recurrence is better than that of patients with sync-oligometastases.
机译：目的：本研究进行了与大全国性研究中的肺同步 - 寡聚菌相比，确认肺部寡聚复发后的优异总存活（OS）。患者和方法：符合以下标准的患者包括：1至5月初立体定向体放射治疗（SBRT）的肺部转移，于2015年1月至2015年6月，以及SBRT的生物有效剂量（床）是75 GY或更多。分析中的参数是年龄，性别，ECOG PS，初级病变，病理学，寡核苷酸州，SBRT日期，化疗在SBRT之前，化疗并发SBRT，化疗后SBRT，最大肿瘤直径，转移数，田间共面，田间共面，剂量处方，床10，SBRT的OTT。结果：总共有1,378名肿瘤患者注册。在1,016名患者，118名患者，同步 - 寡馏分中发生寡聚菌，121例未分类的脱胺酶。对于寡核和寡核和同步 - 寡馏体的三年OS为64.0％（P <0.001）。在多变量分析中，同步 - 寡粒子与寡聚复发的危险比（HR）为1.601（p = 0.014）。 3例患者发生了5级的不良事件。结论：这是第一个全国范围内，表明肺部寡聚患者的OS患者优于同步寡粒子患者的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号